MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, in Advanced NSCLC ...

Galea, H. , Perry, M. and Jones, P. (2026) Characterising Irritable Bowel Syndrome: An Exploratory Cross-Sectional Study .

Viking Therapeutics VKTX announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the GLP-1 and GIP receptors. VKTX is ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...

IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...

In this study, 3,319 unselected, pan-cancer Jordanian patients diagnosed between April 2021 and September 2022 received GGT. Pathogenic germline variant (PGV) frequency among patients who were ...

In a recent study published in the journal Mindfulness, researchers examine the prevalence and effects of emergent phenomena (EP), their forms, the balance of positive and negative repercussions, and ...